Posttranslational modifications of proteins are key features in the identification of CSF biomarkers of multiple sclerosis

Table 6 Sample classification after LDA to discriminate between CSF samples from patients with Relapse–remitting multiple sclerosis (RRMS) and other inflammatory diseases of the CNS (INF) based on the identified protein spots

^aCross validation is done only for those cases in the analysis. In cross validation, each sample is classified by the functions derived from all samples other than the one under analysis
^b91.7% of original grouped cases correctly classified
^c87.5% of cross-validated grouped cases correctly classified

ISSN: 1742-2094